Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations.

Yang M, Schell MJ, Loboda A, Nebozhyn M, Li J, Teer JK, Pledger WJ, Yeatman TJ.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1141-1152. doi: 10.1158/1055-9965.EPI-18-1383. Epub 2019 Apr 23.

PMID:
31015202
2.

Whole Genome Sequencing Analysis of a Stage IV Colon Cancer Patient with a 10-Year Disease-Free Survival following Systemic Chemotherapy/Bevacizumab.

Yeatman TJ, Yang M, Coppola D.

Case Rep Gastroenterol. 2018 Nov 28;12(3):729-736. doi: 10.1159/000494751. eCollection 2018 Sep-Dec.

3.

PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation.

Davis TB, Yang M, Schell MJ, Wang H, Ma L, Pledger WJ, Yeatman TJ.

Sci Rep. 2018 Jun 18;8(1):9296. doi: 10.1038/s41598-018-27584-x.

4.

lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling.

Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z, Singh B, Franklin JL, Wang J, Hu H, Wei T, Yang M, Yeatman TJ, Lee E, Saito-Diaz K, Hinger S, Patton JG, Chung CH, Emmrich S, Klusmann JH, Fan D, Coffey RJ.

Nat Med. 2017 Nov;23(11):1331-1341. doi: 10.1038/nm.4424. Epub 2017 Oct 16.

5.

Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer.

Li C, Singh B, Graves-Deal R, Ma H, Starchenko A, Fry WH, Lu Y, Wang Y, Bogatcheva G, Khan MP, Milne GL, Zhao S, Ayers GD, Li N, Hu H, Washington MK, Yeatman TJ, McDonald OG, Liu Q, Coffey RJ.

Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2852-E2861. doi: 10.1073/pnas.1618297114. Epub 2017 Mar 20.

6.

Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer.

Omolo B, Yang M, Lo FY, Schell MJ, Austin S, Howard K, Madan A, Yeatman TJ.

BMC Med Genomics. 2016 Oct 19;9(1):65.

7.

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.

Schell MJ, Yang M, Teer JK, Lo FY, Madan A, Coppola D, Monteiro AN, Nebozhyn MV, Yue B, Loboda A, Bien-Willner GA, Greenawalt DM, Yeatman TJ.

Nat Commun. 2016 Jun 15;7:11743. doi: 10.1038/ncomms11743.

8.

Adenomatous polyposis coli (APC) regulates miR17-92 cluster through β-catenin pathway in colorectal cancer.

Li Y, Lauriola M, Kim D, Francesconi M, D'Uva G, Shibata D, Malafa MP, Yeatman TJ, Coppola D, Solmi R, Cheng JQ.

Oncogene. 2016 Sep 1;35(35):4558-4568. doi: 10.1038/onc.2015.522. Epub 2016 Jan 25.

9.

A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.

Schell MJ, Yang M, Missiaglia E, Delorenzi M, Soneson C, Yue B, Nebozhyn MV, Loboda A, Bloom G, Yeatman TJ.

Clin Cancer Res. 2016 Feb 1;22(3):734-45. doi: 10.1158/1078-0432.CCR-15-0143. Epub 2015 Oct 7.

10.

Suppression of Reserve MCM Complexes Chemosensitizes to Gemcitabine and 5-Fluorouracil.

Bryant VL, Elias RM, McCarthy SM, Yeatman TJ, Alexandrow MG.

Mol Cancer Res. 2015 Sep;13(9):1296-305. doi: 10.1158/1541-7786.MCR-14-0464. Epub 2015 Jun 10.

11.

Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era.

Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M, Yeatman TJ.

PLoS One. 2015 May 14;10(5):e0126670. doi: 10.1371/journal.pone.0126670. eCollection 2015.

12.

MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance.

Lee CG, McCarthy S, Gruidl M, Timme C, Yeatman TJ.

PLoS One. 2014 Jan 15;9(1):e84597. doi: 10.1371/journal.pone.0084597. eCollection 2014.

13.

Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.

Timme CR, Gruidl M, Yeatman TJ.

Apoptosis. 2013 Oct;18(10):1163-74. doi: 10.1007/s10495-013-0883-x.

PMID:
23887890
14.

Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer.

Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD.

J Natl Cancer Inst. 2011 Dec 21;103(24):1859-70. doi: 10.1093/jnci/djr420. Epub 2011 Dec 8.

15.

Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin.

Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG, Beauchamp RD.

Gastroenterology. 2012 Mar;142(3):562-571.e2. doi: 10.1053/j.gastro.2011.11.026. Epub 2011 Nov 22.

16.

Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer.

Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS.

Gut. 2012 Sep;61(9):1291-8. doi: 10.1136/gutjnl-2011-300812. Epub 2011 Oct 13.

17.

BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma.

Williams CS, Zhang B, Smith JJ, Jayagopal A, Barrett CW, Pino C, Russ P, Presley SH, Peng D, Rosenblatt DO, Haselton FR, Yang JL, Washington MK, Chen X, Eschrich S, Yeatman TJ, El-Rifai W, Beauchamp RD, Chang MS.

J Clin Invest. 2011 Oct;121(10):4056-69. doi: 10.1172/JCI44228. Epub 2011 Sep 12.

18.

Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells.

Singh AB, Sharma A, Smith JJ, Krishnan M, Chen X, Eschrich S, Washington MK, Yeatman TJ, Beauchamp RD, Dhawan P.

Gastroenterology. 2011 Dec;141(6):2140-53. doi: 10.1053/j.gastro.2011.08.038. Epub 2011 Aug 28.

19.

Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas.

Henderson-Jackson EB, Helm J, Strosberg J, Nasir NA, Yeatman TJ, Kvols LK, Coppola D, Nasir A.

Anticancer Res. 2011 Sep;31(9):2957-62.

PMID:
21868544
20.

Expression of the antiapoptotic protein survivin in colon cancer.

Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D.

Clin Colorectal Cancer. 2011 Sep;10(3):188-93. doi: 10.1016/j.clcc.2011.03.014. Epub 2011 Apr 28.

21.

Novel molecular markers of malignancy in histologically normal and benign breast.

Nasir A, Chen DT, Gruidl M, Henderson-Jackson EB, Venkataramu C, McCarthy SM, McBride HL, Harris E, Khakpour N, Yeatman TJ.

Patholog Res Int. 2011;2011:489064. doi: 10.4061/2011/489064. Epub 2011 Jul 10.

22.

RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms.

Nasir A, Helm J, Turner L, Chen DT, Strosberg J, Hafez N, Henderson-Jackson EB, Hodul P, Bui MM, Nasir NA, Hakam A, Malafa MP, Yeatman TJ, Coppola D, Kvols LK.

Pancreas. 2011 May;40(4):627-33. doi: 10.1097/MPA.0b013e3182152bda.

23.

Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation.

Dhawan P, Ahmad R, Chaturvedi R, Smith JJ, Midha R, Mittal MK, Krishnan M, Chen X, Eschrich S, Yeatman TJ, Harris RC, Washington MK, Wilson KT, Beauchamp RD, Singh AB.

Oncogene. 2011 Jul 21;30(29):3234-47. doi: 10.1038/onc.2011.43. Epub 2011 Mar 7.

24.

EMT is the dominant program in human colon cancer.

Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, Van't Veer L, Tollenaar RA, Jackson DB, Agrawal D, Dai H, Yeatman TJ.

BMC Med Genomics. 2011 Jan 20;4:9. doi: 10.1186/1755-8794-4-9.

25.

The 2010 Health Care Reform Act: a potential opportunity to advance cancer research by taking cancer personally.

Dalton WS, Sullivan DM, Yeatman TJ, Fenstermacher DA.

Clin Cancer Res. 2010 Dec 15;16(24):5987-96. doi: 10.1158/1078-0432.CCR-10-1216. Review.

26.

Distinguishing between cancer driver and passenger gene alteration candidates via cross-species comparison: a pilot study.

Ji X, Tang J, Halberg R, Busam D, Ferriera S, Peña MM, Venkataramu C, Yeatman TJ, Zhao S.

BMC Cancer. 2010 Aug 13;10:426. doi: 10.1186/1471-2407-10-426.

27.

Gene expression profiling of colorectal mucinous adenocarcinomas.

Melis M, Hernandez J, Siegel EM, McLoughlin JM, Ly QP, Nair RM, Lewis JM, Jensen EH, Alvarado MD, Coppola D, Eschrich S, Bloom GC, Yeatman TJ, Shibata D.

Dis Colon Rectum. 2010 Jun;53(6):936-43. doi: 10.1007/DCR.0b013e3181d320c4.

PMID:
20485009
28.

Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated with human colorectal adenocarcinomas.

Nam KT, Lee HJ, Smith JJ, Lapierre LA, Kamath VP, Chen X, Aronow BJ, Yeatman TJ, Bhartur SG, Calhoun BC, Condie B, Manley NR, Beauchamp RD, Coffey RJ, Goldenring JR.

J Clin Invest. 2010 Mar;120(3):840-9. doi: 10.1172/JCI40728. Epub 2010 Feb 8.

29.

Copy number abnormalities in sporadic canine colorectal cancers.

Tang J, Le S, Sun L, Yan X, Zhang M, Macleod J, Leroy B, Northrup N, Ellis A, Yeatman TJ, Liang Y, Zwick ME, Zhao S.

Genome Res. 2010 Mar;20(3):341-50. doi: 10.1101/gr.092726.109. Epub 2010 Jan 19.

30.

Genetic risk of breast cancer.

Nasir A, Shackelford RE, Anwar F, Yeatman TJ.

Minerva Endocrinol. 2009 Dec;34(4):295-309. Review.

PMID:
20046159
31.

Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer.

Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D, Aaltonen LA, Arango D, Kruhøffer M, Orntoft TF, Andersen CL, Gruidl M, Kamath VP, Eschrich S, Yeatman TJ, Sieber OM.

Clin Cancer Res. 2009 Dec 15;15(24):7642-7651.

32.

Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.

Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD.

Gastroenterology. 2010 Mar;138(3):958-68. doi: 10.1053/j.gastro.2009.11.005. Epub 2009 Nov 13.

33.

HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability.

Krishnan M, Singh AB, Smith JJ, Sharma A, Chen X, Eschrich S, Yeatman TJ, Beauchamp RD, Dhawan P.

Oncogene. 2010 Jan 14;29(2):305-12. doi: 10.1038/onc.2009.324. Epub 2009 Nov 2.

34.

A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation.

Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Rocha-Lima C, Kelley S, Calvin DP, Yeatman TJ, Begg AC, Torres-Roca JF.

Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):489-96. doi: 10.1016/j.ijrobp.2009.06.014.

35.

Predictive biomarkers: identification and verification.

Yeatman TJ.

J Clin Oncol. 2009 Jun 10;27(17):2743-4. doi: 10.1200/JCO.2008.21.5087. Epub 2009 Mar 30. No abstract available.

PMID:
19332709
36.

Identification of early intestinal neoplasia protein biomarkers using laser capture microdissection and MALDI MS.

Xu BJ, Li J, Beauchamp RD, Shyr Y, Li M, Washington MK, Yeatman TJ, Whitehead RH, Coffey RJ, Caprioli RM.

Mol Cell Proteomics. 2009 May;8(5):936-45. doi: 10.1074/mcp.M800345-MCP200. Epub 2009 Jan 21.

37.

Toward a measure of classification complexity in gene expression signatures.

Kamath V, Yeatman TJ, Eschrich SA.

Conf Proc IEEE Eng Med Biol Soc. 2008;2008:5704-7. doi: 10.1109/IEMBS.2008.4650509.

PMID:
19164012
38.

DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers.

Jorissen RN, Lipton L, Gibbs P, Chapman M, Desai J, Jones IT, Yeatman TJ, East P, Tomlinson IP, Verspaget HW, Aaltonen LA, Kruhøffer M, Orntoft TF, Andersen CL, Sieber OM.

Clin Cancer Res. 2008 Dec 15;14(24):8061-9. doi: 10.1158/1078-0432.CCR-08-1431.

39.

Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution.

Helm JF, Centeno BA, Coppola D, Druta M, Park JY, Chen DT, Hodul PJ, Kvols LK, Yeatman TJ, Carey LC, Karl RC, Malafa MP.

Cancer Control. 2008 Oct;15(4):288-94.

PMID:
18813196
40.

On the eve of personalized medicine in oncology.

Yeatman TJ, Mule J, Dalton WS, Sullivan D.

Cancer Res. 2008 Sep 15;68(18):7250-2. doi: 10.1158/0008-5472.CAN-08-1374. No abstract available.

41.

Long-term results of transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the rectum.

Nair RM, Siegel EM, Chen DT, Fulp WJ, Yeatman TJ, Malafa MP, Marcet J, Shibata D.

J Gastrointest Surg. 2008 Oct;12(10):1797-805; discussion 1805-6. doi: 10.1007/s11605-008-0647-z. Epub 2008 Aug 15.

PMID:
18709419
42.

Proteomic contributions to personalized cancer care.

Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS.

Mol Cell Proteomics. 2008 Oct;7(10):1780-94. doi: 10.1074/mcp.R800002-MCP200. Epub 2008 Jul 29. Review.

43.

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.

Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG.

Nat Med. 2008 Aug;14(8):822-7. doi: 10.1038/nm.1790. Epub 2008 Jul 20.

44.

Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer.

McCarthy S, Caporali A, Enkemann S, Scaltriti M, Eschrich S, Davalli P, Corti A, Lee A, Sung J, Yeatman TJ, Bettuzzi S.

Mol Oncol. 2007 Sep;1(2):196-204. doi: 10.1016/j.molonc.2007.05.007.

45.

Insig2 is associated with colon tumorigenesis and inhibits Bax-mediated apoptosis.

Li CG, Gruidl M, Eschrich S, McCarthy S, Wang HG, Alexandrow MG, Yeatman TJ.

Int J Cancer. 2008 Jul 15;123(2):273-282. doi: 10.1002/ijc.23510.

46.

Src kinase induces tumor formation in the c-SRC C57BL/6 mouse.

Kline CL, Jackson R, Engelman R, Pledger WJ, Yeatman TJ, Irby RB.

Int J Cancer. 2008 Jun 15;122(12):2665-73. doi: 10.1002/ijc.23445.

47.

Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome.

Cheng AS, Culhane AC, Chan MW, Venkataramu CR, Ehrich M, Nasir A, Rodriguez BA, Liu J, Yan PS, Quackenbush J, Nephew KP, Yeatman TJ, Huang TH.

Cancer Res. 2008 Mar 15;68(6):1786-96. doi: 10.1158/0008-5472.CAN-07-5547.

48.

Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation.

Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, Cheng AW, Lin F, Jiang S, Yeatman TJ, Wang XF.

Genes Dev. 2008 Feb 1;22(3):308-21. doi: 10.1101/gad.1632008.

49.

Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome.

Lockhart AC, Harris E, Lafleur BJ, Merchant NB, Washington MK, Resnick MB, Yeatman TJ, Lee W.

Clin Exp Gastroenterol. 2008;1:1-7. Epub 2008 Nov 2.

50.

HPP1-mediated tumor suppression requires activation of STAT1 pathways.

Elahi A, Zhang L, Yeatman TJ, Gery S, Sebti S, Shibata D.

Int J Cancer. 2008 Apr 1;122(7):1567-72.

Supplemental Content

Loading ...
Support Center